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E-mail address: Rummel.Andreas@mh-hannover.dBotulinum neurotoxins (BoNTs) inhibit neurotransmitter release by hydrolysing SNARE proteins
essential for exocytosis. The synaptic vesicle protein synaptotagmin-II of rat and mouse acts as neu-
ronal high afﬁnity receptor for BoNT/B and BoNT/G. Here, we show that human synaptotagmin-II is
not a high afﬁnity receptor for BoNT/B and G due to a phenylalanine to leucine mutation in its lumi-
nal domain present only in humans and chimpanzees. It eliminates one of three major interactions
between synaptotagmin-II and BoNT/B and hereby explains the disparity in potency of BoNT/B in
humans and mice as well as the 40-fold higher dosage of rimabotulinumtoxinB versus onabotuli-
numtoxinA.
Structured summary of protein interactions:
rSyt-II binds to BoNT/G by pull down (View Interaction: 1, 2)
rSyt-II binds to BoNT/B by pull down (View Interaction: 1, 2)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction tive attachment protein receptors of the vesicular fusion machin-Botulinum neurotoxins (BoNTs) are extremely poisonous bacte-
rial protein toxins causing the disease botulism due to blockade of
the acetylcholine release at the neuromuscular junction. On the
other hand they are extensively employed as highly effective med-
icines to treat diseases like cervical dystonia, blepharospasm,
hyperhidrosis and overactive bladder syndrome. The seven BoNT
serotypes A–G are composed of four domains which play individ-
ual roles in their intoxication mechanism. The C-terminal HCC do-
main harbours the two receptor binding sites for gangliosides
and/or a synaptic vesicle protein [1]. The function of the adjacent
HCN domain is the least understood. It can interact with phospha-
tidylinositol phosphates [2] and might trigger the translocation
step [3]. Together, they constitute the 50 kDa HC-fragment which
forms together with the HN domain the 100 kDa heavy chain
(HC). The HN domain spans a pore into the synaptic vesicle mem-
brane thereby translocating the partially unfolded light chain
(LC), a Zn2+ dependent endopeptidase, into the neuronal cytosol
to speciﬁcally hydrolyse certain soluble N-ethlymaleimide sensi-chemical Societies. Published by E
heavy chain; HC, carboxyl-
; HCN, amino-terminal half of
2, synaptic vesicle glycopro-
ptotagmin, respectively; CD,
e (A. Rummel).ery [4]. This results in disruption of the Ca2+ triggered fusion of
synaptic vesicles with the presynaptic membrane thereby blocking
release of acetylcholine.
Local injections of BoNT are widely recognised as themost effec-
tive treatment for cervical dystonia. BoNT/B (rimabotulinumtoxinB)
and BoNT/A (onabotulinumtoxinA) have been shown to be effective
for cervical dystonia inmultiple open-label and controlled trials [5].
Both drugs were compared within the indication cervical dystonia
(CD) using a randomized, double-blind, parallel-arm study design
[6]. Both serotypes had equivalent beneﬁt in subjects with CD at
4 weeks. However, the mean dosage was 205 ± 50 units (U) onabo-
tulinumtoxinA and 8520 ± 1892 U rimabotulinumtoxinB (one U is
deﬁned as one mouse LD50) which corresponds to 40-fold higher
dosageof rimabotulinumtoxinB [6]. Suchhighproteindosage causes
a high frequency of antibody induced therapy failure [7,8]. On the
other hand, the speciﬁc activities in mice were determined to be
20–35 U/ng for onabotulinumtoxinA [9,10] and to be 90–107 U/ng
for rimabotulinumtoxinB [11] which differs only by factor 3–5.
Hence, this approximately 10-fold lowerpotencyof rimabotulinum-
toxinB in human versus mouse has to be attributable to species dif-
ferences on the molecular level. Analysis of the amino acid
sequences 53–92 and 51–90 of VAMP-1 and VAMP-2, respectively,
the neuronal substrates of BoNT/B, revealed 100% identity between
human andmouse VAMP-1 and -2, respectively, excluding impaired
substrate hydrolysis in human [12]. Therefore a difference in recep-
tor recognition might cause the disparity in potency.lsevier B.V. All rights reserved.
Fig. 1. F54 is not conserved in human Syt-II. (A) Sequence alignment of the intraluminal domain of human (h), rat (r), mouse (m) and chimpanzee (c) Syt-II and Syt-I,
respectively. The 17 residues of rSyt-II forming a a-helix upon binding to BoNT/B are underlined. The seven residues mediating the interaction of rSyt-II with BoNT/B are
highlighted in bold. The two residues turning rSyt-I into a high afﬁnity receptor are underlined. The substitution L51 in hSyt-II and cSyt-II corresponding to F54 in rat and
mouse Syt-II is highlighted in green. (B) Binding of the transmembrane juxtaposed 17mer peptide of the intraluminal domain of rSyt-II in an a-helical conformation (amino
acids in orange ball and stick presentation) to the saddle like site in the distal tip of the HCC-domain of BoNT/B (residues in grey stick presentation) (2nm1.pdb). K1192 forms
an important salt bridge to E57 of rSyt-II (dashed line). F54 corresponding to L51 in hSyt-II is highlighted in green ball and stick presentation.
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First, abundant polysialo gangliosides trap and accumulate BoNTs
in the plane of the plasma membrane thus increasing the probabil-
ity to contact their sparsely occurring synaptic vesicle protein
receptors [1]. The intravesicular parts of these proteins are only
temporarily exposed upon fusion of synaptic vesicles at the synap-
tic cleft. BoNT/B and BoNT/G use as their receptors the membrane
juxtaposed 20 amino acids of the intraluminal domain of Synapto-
tagmin (Syt)-I and Syt-II (residues 32–52 and 40–60, respectively)
[15–17], two homologous type I membrane proteins of synaptic
vesicles that link membrane fusion to Ca2+ entry [18–21]. The
mode of interaction of BoNT/B with its protein receptor Syt-II
was elucidated in parallel by co-crystallization of full-length
BoNT/B with a 21mer peptide encoding mouse (m) Syt-II 40-60
[22] and by crystallizing the BoNT/B HC-fragment fused to the pep-
tide encoding rat (r) Syt-II 8-61 [23]. Interestingly, the in solution
unstructured luminal domain of mSyt-II and rSyt-II Syt-II formed
a 17 residue long a-helix upon binding to a saddle like crevice at
the distal tip of the BoNT/B HC-fragment in the direct neighbour-
hood of the single ganglioside binding pocket (Fig. 1B). Only six
hydrophobic residues, especially F47 and F54, of Syt-II interact
via two adjacent pockets in HCB (Fig. 1A). In addition, E57 forms
an important salt bridge with K1192 of HCB. Syt-I has one to two
orders of magnitude lower afﬁnity for BoNT/B compared to Syt-II
[23,24] due to the substitutions Syt-I M47 instead of Syt-II F55and Syt-I L50 instead of Syt-II I58 (Fig. 1A). Double mutation
M47F/L50I converted Syt-I to a Syt-II-like high afﬁnity receptor
thereby substantiating a conserved binding mode for both Syt iso-
forms [23]. Another study evidenced that Syt-I and Syt-II bind to
the equivalent place in BoNT/G [14].
In the present study, we investigated whether amino acid
changes in the intraluminal domains of hSyt-I and hSyt-II could
be responsible for the observed potency difference of BoNT/B in
humans compared to mice. We identiﬁed in the intraluminal do-
main of the BoNT/B high-afﬁnity receptor rSyt-II that F54, which
forms an important interaction with BoNT/B, is mutated to leucine
in hSyt-II and chimpanzee (c) Syt-II. Introduction of the corre-
sponding mutation F54L into rSyt-II abolished its binding to the
HC-fragments of BoNT/B and G in GST-pull-down assays. Hence, a
drastically impaired receptor recognition by BoNT/B provides an
explanation for its decreased potency in humans. Targeted modiﬁ-
cation of the BoNT/B Syt-binding site might improve afﬁnity to
hSyt-II and thereby increase the potency in humans.2. Materials and methods
Fig. 1B was prepared using the programme Discovery Studio
Visualizer 2.5 (Accelrys Software Inc.). Sequence alignment was
made using ClustalW.
Fig. 2. BoNT/B and G HC-fragments do not bind to GST-rSyt-II 1-61 F54L. (A) GST
(25 kDa), GST-rSyt-II 1-61 wild-type (33 kDa) and its mutants F54A and F54L were
immobilised on glutathione-sepharose beads and incubated with HCB and HCG
(50 kDa) for 2 h at 4 C. Proteins bound to the solid phase were visualised by
Coomassie blue staining. (B) Amounts of bound HCB (ﬁlled) and HCG (empty
column) are quantiﬁed (n = 4, ±S.D.).
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Production and puriﬁcation of the HC-fragments of BoNT/B and
G carrying a carboxyl-terminal StrepTag as well as GST-rSyt-II 1-61
were previously described [17,25]. Mutations of GST-rSyt-II were
generated by the Genetailor method (Invitrogen) using suitable
primers and pGEXSytII-61C as template DNA [17]. Nucleotide se-
quences of all mutants were veriﬁed by DNA sequencing.
2.2. GST-pull-down assays
GST-fusion-proteins (150 pmol each) immobilised to 10 ll of
glutathione-sepharose-4B matrix were incubated with recombi-
nant HC-fragments (100 pmol each) in a total volume of 100 ll
20 mM Tris–HCl, 150 mM NaCl, pH 7.2 supplemented with 0.5%
Triton X-100 (Tris/NaCl/Triton) buffer for 2 h at 4 C. Beads were
collected by centrifugation and washed three times each with
160 ll Tris/NaCl/Triton buffer. Washed pellet fractions were boiled
in SDS sample buffer, analysed by 12.5% SDS-polyacrylamide gelelectrophoresis, detected by Coomassie blue staining and subse-
quently quantiﬁed.3. Results and discussion
3.1. Human and chimpanzee Syt-II display a unique single mutation at
position 51
The amino acid sequences of the intraluminal domains of hu-
man, rat, and mouse Syt-I and Syt-II were aligned (Fig. 1A). Accord-
ing to biochemical data and crystallographic studies, only the
membrane juxtaposed 17 amino acids of Syt-I and Syt-II interact
with the HC-fragment of BoNT/B (Fig. 1B) [15,17,22–24]. Here,
F47 and F54 as well as E57 of rSyt-II and mSyt-II form the main
interactions with BoNT/B [22,23]. Identical residues are found
within the homologous segment of human, mouse and rat Syt-I
(F39, F46 and E49). In contrast, residue 51 of human and chimpan-
zee Syt-II corresponding to F54 in mouse and rat Syt-II is a leucine
(Fig. 1A). According to the receptor-toxin structure HCB-rSyt-II, F54
constitutes one of two major hydrophobic interactions with BoNT/
B, and its mutation to alanine completely abolished binding of HCB
in a pull-down assay [23]. Thus, L51 of hSyt-II is a likely candidate
for impaired afﬁnity to BoNT/B and G.3.2. BoNT/B and G HC-fragments do not bind GST-rSyt-II 1-61 F54L
To test the effect of the Phe to Leu replacement at position 51 in
hSyt-II we generated the GST-fusion protein GST-rSyt-II 1-61 F54L
to allow a better comparison with previous binding experiments of
HCB employing rSyt-II. The substitution D52 in rSyt-II versus E52
and E49 in mSyt-II and hSyt-II, respectively, is irrelevant since res-
idue 52 does not interact with HCB and the mutant mSyt-II E52A
displays wild-type binding characteristics [22]. The GST-rSyt-II 1-
61 F54L mutant was recombinantly expressed in Escherichia coli
and could be isolated in yields comparable to the wild-type con-
struct. Subsequently, we performed GST-pull-down assays and
tested the binding of HCB and HCG to the mutant F54L in compar-
ison to wild-type and mutant F54A [23]. HCB and HCG bound to
GST-rSyt-II 1-61 wild-type with 49 ± 14 and 22 ± 9 mol%, respec-
tively (Fig. 2B). The lower afﬁnity of HCG to Syt-II versus HCB is
in accordance with previous data [14,17]. Removing the phenyl
ring of residue 54 (F54A) abolished binding of HCB as well as of
HCG to GST-rSyt-II 1-61 as shown previously [22,23,26]. Finally,
mutant F54L corresponding to hSyt-II similarly deletes binding of
HCB and HCG to GST-rSyt-II 1-61. As F54L is the only replacement
of hSyt-II versus mSyt-II among interacting amino acids, human
Syt-II will bind BoNT/B and G with much lower afﬁnity than mouse
or rat Syt-II. This result underlines the importance of the phenyl
side chain at residue 54 for mediating the hydrophobic interaction
with both BoNT serotypes and is further supported by the muta-
tion of F54 to methionine which also deleted binding with BoNT/
B [26].
In conclusion, this ﬁnding explains the minimum 10-fold lower
potency of BoNT/B in humans compared to mice. Furthermore,
although BoNT/B binds Syt-I with a 10- to 100-fold higher dissoci-
ation constant [23,24], it seems that in humans presumably Syt-I
mediates the neuronal uptake of BoNT/B since the three key resi-
dues (F40, F47 and E50) are conserved in human Syt-I. In addition,
hereby we provide one explanation for the rareness of human bot-
ulism cases caused by BoNT/G [27]. Moreover, this study also sheds
light onto the problematic issue of extrapolating results of animal
experiments or non-human cell line based assays for pharmaceuti-
cal applications in humans. In this case, only experiments in chim-
panzees and no other mammals would have yielded results valid
for humans. In the future, employing the detailed knowledge of
J. Strotmeier et al. / FEBS Letters 586 (2012) 310–313 313BoNT-Syt receptor interaction, one could increase the low binding
afﬁnity to human Syt-II by rationale site directed mutagenesis in
the Syt binding site thereby increasing the potency of BoNT/B in
humans to provide a highly effective alternative treatment for
BoNT/A-non-responding patients with movement disorders.
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